psoriatic arthritis flare; patient went into anaphylaxis after second moderna covid vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PSORIATIC ARTHROPATHY (psoriatic arthritis flare) and ANAPHYLACTIC REACTION (patient went into anaphylaxis after second moderna covid vaccine) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis. Concomitant products included COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) from 01-Jan-2022 to 01-Jan-2022 for COVID-19 vaccination.   On 01-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. In February 2021, the patient experienced ANAPHYLACTIC REACTION (patient went into anaphylaxis after second moderna covid vaccine) (seriousness criterion medically significant). On an unknown date, the patient experienced PSORIATIC ARTHROPATHY (psoriatic arthritis flare) (seriousness criterion medically significant). The patient was treated with METHYLPREDNISOLONE (MEDROL [METHYLPREDNISOLONE]) at an unspecified dose and frequency. At the time of the report, PSORIATIC ARTHROPATHY (psoriatic arthritis flare) was resolving and ANAPHYLACTIC REACTION (patient went into anaphylaxis after second moderna covid vaccine) outcome was unknown.            It was unknown if patient was enrolled in COVID-19 vaccine trial. Company comment: This spontaneous case concerns a 43-year-old, female patient with current medical history of Psoriatic arthritis, who experienced the unexpected, serious (Medically significant) event of Psoriatic arthropathy and expected, serious (Medically significant) event of Anaphylactic reaction. The exact date of onset of the events was not specified in respect to the administration of first and second dose of mRNA-1273, hence latency could not be assessed. The interval between the two doses is 31 days. It has been reported that the patient was medicated with Methylprednisolone of unknown dose and frequency. Details of clinical course and treatment were not provided. The event Psoriatic arthropathy was resolving while the outcome for the event Anaphylactic reaction was unknown at the time of the report. The patient's current medical history of Psoriatic arthritis could be a confounder to the event Psoriatic arthropathy. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.   This case was linked to MOD-2022-682876 (Patient Link).; Sender's Comments: This spontaneous case concerns a 43-year-old, female patient with current medical history of Psoriatic arthritis, who experienced the unexpected, serious (Medically significant) event of Psoriatic arthropathy and expected, serious (Medically significant) event of Anaphylactic reaction. The exact date of onset of the events was not specified in respect to the administration of first and second dose of mRNA-1273, hence latency could not be assessed. The interval between the two doses is 31 days. It has been reported that the patient was medicated with Methylprednisolone of unknown dose and frequency. Details of clinical course and treatment were not provided. The event Psoriatic arthropathy was resolving while the outcome for the event Anaphylactic reaction was unknown at the time of the report. The patient's current medical history of Psoriatic arthritis could be a confounder to the event Psoriatic arthropathy. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.